Immunotoxins hold great promise in future development of prophylaxis and treatment of GVHD because of the potential for selectivity and potency. That they can be effectively utilized to prevent or treat GVHD has been demonstrated, although how significant an impact these agents will ultimately make is yet to be defined. Significant improvements are likely to occur only as our understanding of the biology of GVHD improves, so that we may identify more selective targets and create more effective strategies utilizing targeted therapies.
